A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4200 participants.
Also called NCT06935370
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,200 participants
- Sponsor
- Registry
-
NCT06935370 -
2024-519525-38-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Serbia, Slovakia, South Korea, Spain, Taiwan, Türkiye, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT06935370. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-20 (actual); primary completion 2029-02-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- Condition
- Heart Failure
- Intervention (Drug)
- vicadrostat
- Intervention (Drug)
- empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct06935370- Content hash
fe83661dbd2fa8ffc97497c2270f67d173d316340ed6abd376f869fc990a6518